Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy

NCT: NCT07434492 · NOT_YET_RECRUITING

NCT IDNCT07434492
StatusNOT_YET_RECRUITING
Start Date2026-04-20
Completion2030-08-31

Brief Summary

This is an intervention study to investigate the impact of a smart ankle-foot orthosis (AFO) on mobility outcomes in children with Cerebral Palsy. Participants will complete a three phase protocol including 6-weeks of at home training with the smart AFO. Participants will also have the option to participate in a randomized control trial to investigate the impact of 5-Azacitidine combined with the smart AFO to further effect mobility outcomes.

Frequently Asked Questions

What is Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy?

Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy is a clinical trial registered under NCT07434492. Current status: NOT_YET_RECRUITING.

What is the status of NCT07434492?

The current status of NCT07434492 (Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy) is: NOT_YET_RECRUITING.

When did Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy start?

Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy started on 2026-04-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑